In adults newly diagnosed with a type of blood cancer called core-binding factor acute myeloid leukemia (CBF-AML), genetic mutations present before treatment do not…
News
PANCREATIC CANCER
Cadonilimab combo boosts survival in advanced pancreatic cancer patients
Akeso’s candidate therapy cadonilimab, in combination with chemotherapy, showed encouraging results as a first-line treatment for advanced pancreatic cancer in the Phase 2 COMPASSION-26 study. The…
The European Commission has approved Ipsen’s oral therapy Ojemda (tovorafenib) to treat certain children with pediatric low-grade glioma (pLGG).
GYNECOLOGICAL CANCER
Mo-Rez shows strong early responses in ovarian, endometrial cancers
In an early clinical trial, people with certain advanced or treatment-resistant gynecological cancers showed strong responses to the experimental therapy mocertatug rezetecan (Mo-Rez), according…
The U.S. Food and Drug Administration (FDA) has granted fast track status to Opna Bio‘s OPN-6602 as a potential treatment for people…
AML World Awareness Day, an annual effort to educate people about acute myeloid leukemia (AML), is coming up on April 21, and the advocacy…
PANCREATIC CANCER
Daraxonrasib may offer new hope in previously treated pancreatic cancer
Most people with previously-treated metastatic pancreatic cancer lived for at least one year after receiving the oral therapy candidate daraxonrasib in a clinical trial…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to plixorafenib as a potential treatment for adults with high-grade gliomas carrying…
GYNECOLOGICAL CANCER
New Keytruda regimen OK’d in EU for hard-to-treat gynecological cancers
A new regimen using the immunotherapy Keytruda (pembrolizumab) has been approved in the European Union for use by certain people with hard-to-treat gynecological…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Telix Pharmaceuticals seeking approval of TLX101-Px, the company’s experimental imaging…
Recent Posts
- Study of gynecological cancer therapy moving fast in summer slowdown
- The caregiver’s invisible ledger tracks what no one else sees
- Study shows protein marker helps predict aggressive myeloma
- New combination therapy cuts risk of death in hard-to-treat myeloma
- Early AML trial finds experimental therapy was generally well tolerated
